ClinicalTrials.gov
ClinicalTrials.gov Menu

Reproducibility Study of Over Active Bladder Symptom Score [OABSS] (RESORT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00901251
Recruitment Status : Completed
First Posted : May 13, 2009
Last Update Posted : March 15, 2011
Sponsor:
Collaborator:
Astellas Pharma China, Inc.
Information provided by:
Astellas Pharma Inc

May 11, 2009
May 13, 2009
March 15, 2011
January 2009
May 2009   (Final data collection date for primary outcome measure)
OABSS [ Time Frame: Weeks of 0 and 2 ]
Same as current
Complete list of historical versions of study NCT00901251 on ClinicalTrials.gov Archive Site
3-day micturition diary [ Time Frame: 2 times in 2-week interval ]
Same as current
Not Provided
Not Provided
 
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
Reproducibility Study of OABSS and Its Response to Treatment - Part 1: Reproducibility -
The purpose of this study is to evaluate the reproducibility of over active bladder symptom score (OABSS) in Asian countries.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Symptomatic OAB patients having urgency episodes
Overactive Bladder
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Same as current
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptoms OAB for 3 months or longer
  • At least 1 urgency episode in last 3 days
  • Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:

    • Number of micturition ≥8 times/day
    • Number of urgency episode in 3 days ≥1

Exclusion Criteria:

  • Indwelling catheters or practicing intermittent self-catheterization
  • Symptomatic urinary tract infection, chronic inflammation
  • Diabetic neuropathy
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00901251
VESOABCN02
No
Not Provided
Not Provided
Disclosure Director, Astellas Pharma, Inc
Astellas Pharma Inc
Astellas Pharma China, Inc.
Study Chair: Use Central Contact Astellas Pharma China, Inc.
Astellas Pharma Inc
March 2011